Search - tctmd.com

Displaying 1 - 20 of 502

Sort: Relevancy | Date

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

DCB in STEMI Match DES Through 5 Years: REVELATION

Caitlin E. Cox

March 27, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Advertisement

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

What’s Going to Be Hot at TCT 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Top Coronary Artery Disease News in 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

DES Best for In-Stent Restenosis, but DCBs Also Viable

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

FDA Approves Bioresorbable Scaffold for BTK Lesions

DCB in STEMI Match DES Through 5 Years: REVELATION

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content